Janssen-Heijnen M L, Gatta G, Forman D, Capocaccia R, Coebergh J W
Eindhoven Cancer Registry, The Netherlands.
Eur J Cancer. 1998 Dec;34(14 Spec No):2191-6. doi: 10.1016/s0959-8049(98)00312-8.
In this study, we report on the variation in the prognosis for adult patients with lung cancer within Europe, by age, histology and country from 1985-1989. We considered trends in survival since 1978 for most countries. Survival analysis was carried out on 173,448 lung cancer cases diagnosed between 1985 and 1989 in 44 population-based cancer registries, participating in the EUROCARE study. Relative 1-year survival rates for patients with lung cancer varied from 24 to 40%, being highest in Finland, France, The Netherlands and Switzerland and lowest in Denmark, England, Poland and Scotland. Half of all patients under the age of 45 years died within 1 year of diagnosis, increasing to almost 80% for those aged 75 years or older. Whilst the prognosis for patients with non-small cell carcinoma remained more or less constant between 1978 and 1989 (25% in Denmark and 44% in Finland), that for patients with small cell carcinoma improved slightly, especially in The Netherlands (Eindhoven from 17 to 24%) and Switzerland (Geneva from 24 to 32%). In conclusion, a fairly large variation in lung cancer relative survival rates existed between European countries. The most likely explanation for the differences is the variation in access to specialised care. Except for a slight improvement in short-term survival for patients with small cell lung cancer, survival has remained poor since 1978.
在本研究中，我们报告了1985年至1989年间欧洲成年肺癌患者的预后情况，按年龄、组织学类型和国家进行了分析。我们考虑了大多数国家自1978年以来的生存趋势。对参与EUROCARE研究的44个基于人群的癌症登记处1985年至1989年间诊断出的173448例肺癌病例进行了生存分析。肺癌患者的相对1年生存率在24%至40%之间，在芬兰、法国、荷兰和瑞士最高，在丹麦、英国、波兰和苏格兰最低。所有45岁以下的患者中有一半在诊断后1年内死亡，75岁及以上的患者这一比例增至近80%。虽然非小细胞癌患者的预后在1978年至1989年间大致保持不变（丹麦为25%，芬兰为44%），但小细胞癌患者的预后略有改善，尤其是在荷兰（埃因霍温从17%升至24%）和瑞士（日内瓦从24%升至32%）。总之，欧洲国家之间肺癌相对生存率存在相当大的差异。差异最可能的解释是获得专科护理的差异。除了小细胞肺癌患者的短期生存率略有改善外，自1978年以来生存率一直很低。
